Figure 1 - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Incidence of soft-tissue sarcoma as a function of age in France. Cases per 100,000 inhabitants per year; age groups (years).
Source publication
Four thousand new cases of soft tissue sarcomas are diagnosed each year in France, 23% of which are localized in the abdomen and pelvis; the treatment of non-metastatic tumor is based on wide surgical resection, the quality of which determines the long-term outcome. To ensure appropriate care, the European Society of Medical Oncology (ESMO) recomme...
Context in source publication
Context 1
... of visceral sarcomas (1.4/1) and a male preponderance for STS (1.3/1). The median age at diagnosis was 60 years, with a range between 0 and 92 years. Eight percent of patients developed sarcoma before the age of 18, and 28% after the age of 70 years. A graphical representation of the evolution according to age of the incidence of STS is shown in Fig. 1. The median size of the lesion was 6 cm, with extremes ranging from 0.3-40 cm. Localization of STS was truncal in 40% of cases (17% thoracic, 9% retroperitoneal, 8% pelvic and 6% abdominal), while 60% of STS were peripheral (49% localized on a limb and 11% on the head and neck). Of the 433 diagnosed cases of STS, 25 (5.8%) arose in ...
Citations
... 37,38 Several environmental genotoxic agents-such as vinyl chloride, dioxin, and chlorophenolhave been investigated for their potential promoting role in the STS pathogenesis. 39,40 Exposure to pesticides is one of the most extensively examined factors in epidemiological studies, with considerable attention being paid to the potentially harmful effects of phenoxy herbicides and chlorophenols due to an excess incidence and mortality seen for certain cancers, including STS, in exposed workers. 37 STS is also one of the few tumors specifically linked to dioxins, and 2,3,7,8tetrachlorodibenzo-p-dioxin, considered the most potent dioxin, is classified as a group 1 carcinogen by the International Agency for Research on Cancer. ...
Background
There are evident sex differences in the incidence of and mortality rates for several tumors. Soft tissue sarcomas (STSs) account for no more than 1% of all malignancies in adults. This study aimed to provide a comprehensive overview of the sex differences in the epidemiology of STSs and the related costs.
Methods
This retrospective population-based study draws on epidemiological data regarding cases of STS collected by the cancer registry of the Italian Veneto region for the years 1990–2018. A joinpoint regression analysis was performed to identify significant changes in the trends of the standardized incidence rates in males and females. Bivariate and survival analyses were conducted to assess differences in clinicopathological characteristics and short-term mortality by sex. Direct health care costs incurred over 2 years after a diagnosis of STS were calculated, stratified by sex.
Results
The incidence rates of STS at any age were higher for males; only among males the incidence rates showed a tendency to slightly increase. No significant sex differences came to light in short-term mortality or clinicopathological profile, except for the cancer site. Health care costs in the 2 years after a diagnosis of STS were not sex related.
Conclusion
The STS incidence was found to be higher for males and showed a rising trend over the last three decades only for males. These findings could result from the occupational exposure to environmental mutagens mainly involving men. Sex did not affect the survival or the clinicopathological STS profile.
... The crude incidence of sarcomas in Europe between 1995 and 2002 was 56 cases per million individuals per year [3]. In France, the crude incidence of soft tissue sarcomas alone was 62 cases per million individuals per year [29]. A slight predisposition to have sarcomas in males was observed in this study, which was also observed in other European studies [3,4,20]. ...
Sarcomas are a heterogeneous group of mesenchymal malignancies with various genetic and environmental risk factors. This study analyzed the epidemiology of sarcomas to gain insight into the incidence and mortality rates of these cancers in Canada, as well as to elucidate their potential environmental risk factors. Data for this study were obtained from le Registre Québécois du Cancer (LRQC) and from the Canadian Cancer Registry (CCR) for the period from 1992 to 2010. Mortality data were obtained from the Canadian Vital Statistics (CVS) database for the period from 1992 to 2010 using the International Classification of Diseases for Oncology, ICD-O-3, ICD-9, or ICD-10 codes, for all subtypes of sarcomas. We found that the overall sarcoma incidence in Canada decreased during the study period. However, there were select subtypes with increasing incidence. Peripherally located sarcomas were found to have lower mortality rates compared to axially located sarcomas, as expected. Clustering of Kaposi sarcoma cases in self-identified LGBTQ+ communities and in postal codes with a higher proportion of African-Canadian and Hispanic populations was observed. Forward Sortation Area (FSA) postal codes with a lower socioeconomic status also had higher Kaposi sarcoma incidence rates.
... Sarcomas are rare malignant tumors that originate from mesenchymal cells. In France, the annual incidence is approximately 4,000 new cases [8]. These tumors can develop in either the bone or soft tissues, with the limbs being the primary location [9]. ...
Multidisciplinary tumor board meetings (MTBMs) have been established in oncology to improve patient care. While their benefits for patients have been well-documented, there are no previous studies on the teaching opportunities they provide for residents and medical students. This study aimed to examine the teaching provided to residents during MTBM and identify areas for improvement. The study hypothesized that although the primary objective of MTBM is not teaching, they could still contribute to residents' learning. The study focused on the tumors board meeting for bone metastasis and musculoskeletal tumors/sarcoma in a French reference center for musculoskeletal oncology. The composition of the MTBM included specialists from various disciplines, and it convened on a weekly basis to discuss cases. The orthopedic oncology residents (OORs) actively participated in the MTBM as part of their training. A questionnaire was distributed to OORs who had served between 2014 and 2021, and their responses were analyzed. The results showed that the OOR perceived MTBM as interesting, beneficial for their training, and challenging. While opinions were divided on whether MTBM was a suitable place for education, the majority believed it improved their knowledge of different specialties and provided valuable elements applicable to daily practice. They also felt it facilitated future access to MTBs if needed. OORs recommended the rotation as an orthopedic oncology resident to younger residents. Recommendations for improvement included incorporating more dedicated teaching time, active involvement of residents in the learning process, availability of learning materials, and post-MTBM debriefing sessions. The study highlighted the importance of case presentations, public speaking skills, interdisciplinary collaboration, and clinical reasoning observed during MTBM. In conclusion, while not primarily designed for teaching, MTBM offers valuable learning opportunities for residents. Enhancing the teaching experience through dedicated debriefing sessions, resident involvement, and improved support can further optimize their educational impact. Future evaluations are needed to assess the effectiveness of these improvements. This study provides insights into the teaching potential within MTBM and can guide educational initiatives in the field of oncology.
... 5 Soft tissue cancers have a wide range of pathologies (close to 70 types) and can affect people of any age and in any anatomical location. 6 In Europe, the prevalence of soft tissue cancer is higher than the prevalence of bone cancer, Incidence of bone and soft tissue cancers in Golestan, Iran and both types are more common in men than women. 7 Most types of bone cancers occur sporadically. ...
Background:
This study was conducted to evaluate the epidemiological features of bone and soft cancers in the Golestan province, Northern Iran from 2004 to 2016.
Methods:
This is a descriptive cross-sectional study. All patients with primary bone and soft tissue cancers between 2004 and 2016 were included. Data were obtained from Golestan population-based cancer registry (GPCR). We calculated age-standardized incidence rates (ASRs) and reported the rates per 100000 person-year. Estimated annual percent change (EAPC) was also calculated to assess temporal trends in incidence rates of these cancers.
Results:
The ASRs of bone cancers and soft tissue cancers were 1.33 and 1.43 per 100000 person-year, respectively. This study also showed that the ASR of bone cancer was higher in men (1.51) than women (1.15). The ASR of soft tissue cancers in the urban population (1.58) was higher than rural (1.27), and was lower in women (1.37) than men (1.49). Two peaks were seen in the incidence of bone cancer. The first peak was in the age group of 10 to 20 years and the second was in patients over 60. We did not find significant temporal trends in the incidence of bone (EAPC=-1.14; P>0.05) and soft tissue cancers (EAPC=-2.73; P>0.05) during the study period.
Conclusion:
Epidemiological features of bone and soft tissue cancers including gender, age and place of residence should be considered by health policy makers in designing cancer control programs.
... Saltus et al. [12] as the median age was above 50 years old and more common in the lower extremities but in our study female patients were more than male patients. In a 2015 study of soft tissue sarcomas in France Honoré et al. [13] reported that 40% of cases were truncal (17% thoracic, 9% retroperitoneal, 8% pelvic, and 6% abdominal), whereas 60% of cases were peripheral (49% on a limb and 11% head and neck) which looks like our study as extremities' sarcoma were 62% and visceral plus retroperitoneal were 38%, we found that most common histological type was 19%, liposarcoma were 13%, fibro sarcoma were 11%, GIST was 19% and leiomyosarcoma was 9% unlikely the current study, liposarcoma was the most common STS in Japan accounting for 32.5% of cases. However, the order of frequency of the various liposarcoma subtypes was different (myxoid/round cell, followed by dedifferentiated, then well-differentiated subtype in the Japanese study versus well-differentiated, followed by myxoid/round cell, followed by well-differentiated subtype in the current study). ...
... The mean incidence of retroperitoneal sarcoma is 2.7 per million [2]. In fact, softtissue sarcomas which are mesenchymal neoplasms account for up to 1% of all newly diagnosed malignancies at a rate of 3.6 per 100,000 per year and visceral sarcoma of 2.0 cases per 100,000 population per year [3,4]. The overall male to female ratio was 1.1:1; nevertheless, a female predominance of visceral sarcomas was recorded at rate of 1.4: 1; whereas a (1.3: 1) of male preponderance for soft tissue sarcoma in general is found [4]. ...
... In fact, softtissue sarcomas which are mesenchymal neoplasms account for up to 1% of all newly diagnosed malignancies at a rate of 3.6 per 100,000 per year and visceral sarcoma of 2.0 cases per 100,000 population per year [3,4]. The overall male to female ratio was 1.1:1; nevertheless, a female predominance of visceral sarcomas was recorded at rate of 1.4: 1; whereas a (1.3: 1) of male preponderance for soft tissue sarcoma in general is found [4]. ...
... They are considered rare as only 9-15% of all adult soft tissue sarcomas (STS) present in the retroperitoneum [3]. There are three principal kinds of sarcoma corresponding to different clinicopathological entities with specific progression, and individual different management means: bone sarcomas, visceral sarcomas that develop in a specific organ and soft tissue sarcomas (STS) arising in connective tissue and extra-osseous connective tissue; these represent about 1% of all adult cancers [4]. ...
Retroperitoneal sarcomas are rare soft tissue tumors that account for only 1%-2% of all solid tumors. The majority of sarcomas occur outside of the retroperitoneum. Retroperitoneal sarcomas account for 10%-20% of all sarcomas, with an overall incidence of 0.3%-0.4% per 100,000 people. Although they can occur at any age, they are most common in the fifth decade of life. The established diagnosis is based on CT or MR imaging, which is used in patients with these tumors to detect local and distant metastases as well as for preoperative surgical planning. Surgery is the most common form of treatment for retroperitoneal sarcoma. And the surgical team discussed the condition of a 28-year-old patient who had been hospitalized.
... The mean incidence of retroperitoneal sarcoma is 2.7 per million [2]. In fact, softtissue sarcomas which are mesenchymal neoplasms account for up to 1% of all newly diagnosed malignancies at a rate of 3.6 per 100,000 per year and visceral sarcoma of 2.0 cases per 100,000 population per year [3,4]. The overall male to female ratio was 1.1:1; nevertheless, a female predominance of visceral sarcomas was recorded at rate of 1.4: 1; whereas a (1.3: 1) of male preponderance for soft tissue sarcoma in general is found [4]. ...
... In fact, softtissue sarcomas which are mesenchymal neoplasms account for up to 1% of all newly diagnosed malignancies at a rate of 3.6 per 100,000 per year and visceral sarcoma of 2.0 cases per 100,000 population per year [3,4]. The overall male to female ratio was 1.1:1; nevertheless, a female predominance of visceral sarcomas was recorded at rate of 1.4: 1; whereas a (1.3: 1) of male preponderance for soft tissue sarcoma in general is found [4]. ...
... They are considered rare as only 9-15% of all adult soft tissue sarcomas (STS) present in the retroperitoneum [3]. There are three principal kinds of sarcoma corresponding to different clinicopathological entities with specific progression, and individual different management means: bone sarcomas, visceral sarcomas that develop in a specific organ and soft tissue sarcomas (STS) arising in connective tissue and extra-osseous connective tissue; these represent about 1% of all adult cancers [4]. ...
Retroperitoneal sarcomas are rare soft tissue tumors that account for only 1%-2% of all solid tumors. The majority of sarcomas occur outside of the retroperitoneum. Retroperitoneal sarcomas account for 10%-20% of all sarcomas, with an overall incidence of 0.3%-0.4% per 100,000 people. Although they can occur at any age, they are most common in the fifth decade of life. The established diagnosis is based on CT or MR imaging, which is used in patients with these tumors to detect local and distant metastases as well as for preoperative surgical planning. Surgery is the most common form of treatment for retroperitoneal sarcoma. And the surgical team discussed the condition of a 28-year-old patient who had been hospitalized.
... Soft tissue sarcomas (STS), one of the two major subclasses of sarcoma, arise from diverse connective tissue and are more frequently diagnosed than bone sarcomas, which arise from bone or cartilage [4,5]. Due to its rarity and heterogenicity, it is likely that STS incidences are underestimated and initially misdiagnosed which could adversely affect patient outcomes [6][7][8]. ...
Soft tissue sarcomas (STS) are a rare and highly heterogeneous group of solid tumors, originating from various types of connective tissue. Complete removal of STS by surgery is challenging due to the anatomical location of the tumor, which results in tumor recurrence. Additionally, current polychemotherapeutic regimens are highly toxic with no rational survival benefit. Cold atmospheric plasma (CAP) is a novel technology that has demonstrated immense cancer therapeutic potential. Canady Cold Helios Plasma (CHCP) is a device that sprays CAP along the surgical margins to eradicate residual cancer cells after tumor resection. This preliminary study was conducted in vitro prior to in vivo testing in a humanitarian compassionate use case study and an FDA-approved phase 1 clinical trial (IDE G190165). In this study, the authors evaluate the efficacy of CHCP across multiple STS cell lines. CHCP treatment reduced the viability of four different STS cell lines (i.e., fibrosarcoma, synovial sarcoma, rhabdomyosarcoma, and liposarcoma) in a dose-dependent manner by inhibiting proliferation, disrupting cell cycle, and inducing apoptosis-like cell death.
... This observation demonstrates the importance of a reevaluation of diagnostics by a specialized musculoskeletal surgeon. This results in a better outcome at a specialized center with experience regarding rare tumor diseases [21][22][23]. ...
Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the individual diagnostic and therapeutic procedures. Overall, 38 patients were included in the study. IMMs occurred mostly in middle-aged women. At the time of first consultation, 57.9% had few symptoms or were asymptomatic. In 92.1% of the cases, the tumor was localized in the extremities. The lower extremity was affected in 73.7%. The average size of IMMs was 5.0 cm. The proximally located tumors in the gluteus, thighs, and upper arms were significantly larger (p = 0.02) than the distally-located tumors in the forearms and lower legs. An MRI was performed in 97.4%. Based on imaging, an IMM was suspected in 5.6% by radiologists and in 54.1% by musculoskeletal surgeons. An incision biopsy was performed in 68.4% and led in 100.0% to the right histopathological diagnosis. In total, 89.5% of IMMs were resected. Postoperative complications requiring revision occurred in 8.8%. Recurrences or degenerations of IMMs were not reported in any of these cases.
... Etiology of the majority of STS is unknown, but several genetic syndromes, like Li-Fraumeni syndrome or Neurofibromatosis type 1, and also environmental risk factors, like ionizing radiation or chemical exhibitors, are related to an increased risk [5][6][7]. ...
Magnetic Resonance Imaging is a fundamental tool in the evaluation of soft tissue sarcoma. Imaging features are relevant for the assessment of treatment strategies, surgical planning and also for patients’ prognosis prediction. Among soft tissue sarcoma and also other malignancies, the size of the mass is usually considered the prognostic key element in diagnostic imaging. Moreover, several other features should be obtained from MRI studies with prognostic implications in all type of soft tissue sarcoma: peritumoral enhancement, signs of necrosis, deep location, ill-defined borders/signs of infiltrations. Focusing on soft tissue sarcoma subtypes, some other magnetic resonance imaging features are more specific and related to prognosis. In myxofibrosarcoma the magnetic resonance imaging “tail sign” and a “water-like” appearance on fluid-sensitive sequences, due to rich myxoid matrix content, are both associated with higher risk of local recurrence after surgical excision; nevertheless, the “tail sign” is also related to a higher risk of distant metastases at diagnosis. The “tail sign” is associated with higher risk of local recurrence after surgical excision in undifferentiated pleomorphic sarcoma as well. In patients affected by synovial sarcoma, the “triple sign” identifiable in magnetic resonance imaging (T2w sequences) is associated with decreased disease-free survival and indicates the simultaneous presence of solid cellular elements (intermediate signal intensity), hemorrhage or necrosis (high signal intensity) and fibrotic regions (low signal intensity). In addition, absence of calcifications are associated with reduced disease-free survival in patients affected by synovial sarcoma. Signal heterogeneity is associated with worst prognosis in all type of soft tissue sarcoma, particularly in myxoid liposarcoma. In recent years, several new quantitative tools applied on magnetic resonance imaging have been proved to predict patients’ prognosis. Above all the new tools, radiomics seems to be one of the most promising, and, has been proved to have the capability in discriminating low-grade from high-grade soft tissue sarcomas. Therefore, magnetic resonance imaging studies in patients with soft tissue sarcoma should be accurately evaluated and their results should be taken into account for prognostic assessment.
